scholarly journals The Degree of Plasma Oxidized Low-Density Lipoprotein Level Decrease Is Related to Clinical Outcomes for Patients with Acute Ischemic Stroke

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Xiaoli Yang ◽  
Wenbo Sun ◽  
Duanlu Hou ◽  
Tianyao Wang ◽  
Chen Li ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Clinical Outcomes ◽  
Statistical Difference ◽  
Infarct Volume ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Oxidized Low Density Lipoprotein ◽  
Neurological Improvement ◽  
Oxldl Level ◽  
Level Group

Objective. To investigate the relationship between the decrease of plasma oxidized low-density lipoprotein (oxLDL) levels and clinical outcomes in patients with acute atherosclerosis-related ischemic stroke. Methods. We recruited acute ischemic stroke patients within 3 days of onset consecutively. Plasma oxLDL levels were measured on the second day after admission and before discharge (10-14 days after stroke onset). Initial stroke severity was assessed by the National Institutes of Health Stroke Scale (NIHSS) scores, and infarct volume was measured using diffusion-weighted imaging (DWI) by the ITK-SNAP software. Clinical outcomes were evaluated by DWI volumes in the acute phase, neurological improvement at discharge, and favorable functional prognosis at 90 days. Logistic regression was performed to evaluate the association between oxLDL level decrease and clinical outcomes. Results. 207 patients were enrolled in this study. Compared with the mild decrease of the oxLDL level group, patients with a significant decrease of the oxLDL level group were more likely to have a higher ratio of neurological improvement at discharge (55.07% vs. 14.49%, p < 0.01 ) and favorable functional prognosis at 90 days (91.30% vs. 55.07%, p < 0.01 ). In multivariable logistic regression, the degree of oxLDL level decrease was related to neurological improvement at discharge and favorable functional prognosis at 90 days ( p < 0.01 ). Patients with significant decrease were more likely to have neurological improvement at discharge ( OR = 7.92 , 95% CI, 3.14-19.98, and p < 0.01 ) and favorable functional prognosis at 90 days ( OR = 7.46 , 95% CI, 2.40-23.23, and p < 0.01 ) compared to patients with mild decrease of oxLDL level. The DWI volumes in patients with different oxLDL level decrease groups had no statistical difference ( p = 0.41 ), and the Spearman’s rho between oxLDL level decrease and DWI infarct volumes was -0.03, but no statistical difference ( p = 0.72 ). Conclusions. The degree of oxLDL level decrease is related to neurological improvement at discharge and favorable functional prognosis at 90 days for patients with acute atherosclerosis-related ischemic stroke, but not with infarct volume in the acute phase.

scholarly journals Change of Plasma Oxidized Low-Density Lipoprotein Level Predicts Clinical Outcome at 90 Days for Patients with Acute Ischemic Stroke

2021 ◽  
Author(s):  
Xiaoli Yang ◽  
Wenbo Sun ◽  
Duanlu Hou ◽  
Tianyao Wang ◽  
Chen Li ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Infarct Volume ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Oxidized Low Density Lipoprotein ◽  
Neurological Improvement ◽  
Level Change ◽  
Oxldl Level ◽  
Level Group

Abstract Objectives: To investigate the relationship between change of plasma oxidized low-density lipoprotein (oxLDL) level and clinical outcomes in patients with acute atherosclerosis related ischemic stroke. Methods: We recruited acute ischemic stroke patients within 3 days after onset consecutively. Plasma oxLDL level were measured on the second day after admission and before discharge. Initial stroke severity was assessed by the National Institutes of Health Stroke Scale(NIHSS) scores, and infarct volume was measured using diffusion weighted imaging (DWI) by ITK-SNAP software. Clinical outcomes were evaluated by neurological improvement at discharge and favorable functional prognosis at 90 days. Results: 207 patients were enrolled into this study. Compared with mild change of oxLDL level group, patients with significant change oxLDL level group were more likely to have higher ratio of neurological improvement at discharge(55.07% vs 14.49%) and favorable functional prognosis at 90 days(91.30% vs 55.07%). The DWI volumes in patients with different oxLDL level change groups were no statistical difference. In multivariable logistic regression, the degree of oxLDL level change was related with neurological improvement at discharge and favorable functional prognosis at 90 days. Compared to patients with mild change of oxLDL level, patients with significant change were more likely to have neurological improvement at discharge(OR=7.21,95%, 3.09-16.80, p <0.01) and favorable functional prognosis at 90 days (OR=6.67, 95%CI, 2.15-20.73, p <0.01).Conclusions: The degree of oxLDL level change is related to the neurological improvement at discharge and favorable functional prognosis at 90 days for patients with acute atherosclerosis related ischemic stroke, but not with infarct volume.

scholarly journals Prestroke statins use reduces oxidized low density lipoprotein level and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke

2019 ◽  
Author(s):  
lanying he ◽  
Ronghua Xu ◽  
Jian Wang ◽  
LIli Zhang ◽  
Lijuan Zhang ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Ischemic Stroke ◽  
Confidence Interval ◽  
Clinical Outcomes ◽  
Odds Ratio ◽  
Adjusted Odds Ratio ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Oxidized Low Density Lipoprotein

Abstract Background Atrial fibrillation (AF) is a common cause of cerebral infarction, which could lead to endothelial dysfunction, increased reactive oxygen species (ROS) and oxidized low density lipoprotein (Ox-LDL).AF is associated with higher mortality and more severe neurologic disability. Statins may exert neuroprotective effects that are independent of LDL-C lowering. The purpose of our study was to investigate whether prestroke statins use could reduce plasma Ox-LDL level and improve clinical outcomes in patients with AF related acute ischemic stroke(AIS). Methods This was a multicenter consecutive trial that involved four medical centers, 242 AIS patients with AF were identified, who underwent a comprehensive clinical investigation and a 72h-Holter electrocardiogram monitoring. All patients were divided into two groups: prestroke statins use and no prestroke statins use groups, who were followed up for 3 months. Ox-LDL was measured using enzyme-linked immunosorbent assay (ELISA) on admission and 3 months. The outcome was death or major disability (modified Rankin Scale score≥3) at 3 months after AIS. Results Plasma Ox-LDL level was significantly lower in prestroke statins use than in no prestroke statins use on admission (P=0.001). Plasma Ox-LDL level on admission were associated with 3-month outcome(P<0.05).In fully adjusted models, prestroke statins use was associated with reduced 3-month mortality (adjusted odds ratio, 0.43; 95% confidence interval, 0.20–0.93; P=0.031), major disability (adjusted odds ratio, 0.33; 95% confidence interval, 0.13–0.82; P=0.017), and composite outcome (adjusted odds ratio, 0.25; 95% confidence interval,0.11–0.56; P=0.001). Conclusions Prestroke statins use can reduce plasma Ox-LDL level and improve clinical outcomes in patients with AF related AIS.

scholarly journals Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke

BMC Neurology ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Lanying He ◽  
Ronghua Xu ◽  
Jian Wang ◽  
Lili Zhang ◽  
Lijuan Zhang ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Clinical Outcomes ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Low Density ◽  
Composite Outcome ◽  
Oxidized Low Density Lipoprotein

Abstract Background Atrial fibrillation (AF) is a common cause of cerebral infarction, which could lead to endothelial dysfunction, increased reactive oxygen species (ROS) and oxidized low density lipoprotein (Ox-LDL).AF is associated with higher mortality and more severe neurologic disability. Statins may exert neuroprotective effects that are independent of LDL-C lowering. The purpose of our study was to investigate whether prestroke statins use could reduce plasma Ox-LDL levels and improve clinical outcomes in patients with AF-related acute ischemic stroke (AIS). Methods This was a multicenter prospective study that involved four medical centers, 242 AIS patients with AF were identified, who underwent a comprehensive clinical investigation and a 72 h-Holter electrocardiogram monitoring. All patients were divided into two groups: prestroke statins use and no prestroke statins use groups, who were followed up for 3 months. Plasma Ox-LDL levels were measured using enzyme-linked immunosorbent assay (ELISA) on admission and at 3 months. The outcome was death, major disability (modified Rankin Scale score ≥ 3), and composite outcome (death/major disability) at 3 months after AIS. Results One hundred thirty-six patients were in no prestroke statins use group, and 106 in prestroke statins use group. Plasma Ox-LDL levels were significantly lower in prestroke statins use than in no prestroke statins use on admission and at 3 months (P < 0.001). Plasma Ox-LDL levels on admission were associated with 3-month mortality [adjusted odds ratio (OR), 1.05; 95% confidence interval (CI), 0.99–1.12; P = 0.047]. In fully adjusted models, prestroke statins use was associated with reduced 3-month mortality [adjusted OR, 0.38; 95% CI, 0.16–0.91; P = 0.031)], major disability (adjusted OR, 0.38; 95% CI, 0.15–0.99; P = 0.047), and composite outcome (adjusted OR, 0.31; 95% CI, 0.17–0.74; P = 0.009). Conclusions Prestroke statins use can reduce plasma Ox-LDL levels and improve clinical outcomes in patients with AF-related AIS.

scholarly journals Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke

2019 ◽  
Author(s):  
lanying he ◽  
Ronghua Xu ◽  
Jian Wang ◽  
LIli Zhang ◽  
Lijuan Zhang ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Clinical Outcomes ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Low Density ◽  
Composite Outcome ◽  
Oxidized Low Density Lipoprotein

Abstract Background: Atrial fibrillation (AF) is a common cause of cerebral infarction, which could lead to endothelial dysfunction, increased reactive oxygen species (ROS) and oxidized low density lipoprotein (Ox-LDL).AF is associated with higher mortality and more severe neurologic disability. Statins may exert neuroprotective effects that are independent of LDL-C lowering. The purpose of our study was to investigate whether prestroke statins use could reduce plasma Ox-LDL levels and improve clinical outcomes in patients with AF-related acute ischemic stroke (AIS). Methods: This was a multicenter prospective study that involved four medical centers, 242 AIS patients with AF were identified, who underwent a comprehensive clinical investigation and a 72h-Holter electrocardiogram monitoring. All patients were divided into two groups: prestroke statins use and n o prestroke statins use groups , who were followed up for 3 months. Plasma Ox-LDL levels were measured using enzyme-linked immunosorbent assay (ELISA) on admission and at 3 months. The outcome was death, major disability (modified Rankin Scale score≥3), and composite outcome (death/major disability) at 3 months after AIS. Results: 136 patients were in no prestroke statins use group, and 106 in prestroke statins use group . Plasma Ox-LDL levels were significantly lower in prestroke statins use than in no prestroke statins use on admission and at 3 months (P<0.001). Plasma Ox-LDL levels on admission were associated with 3-month mortality [adjusted odds ratio (OR), 1.05; 95% confidence interval(CI), 0.99-1.12; P=0.047]. In fully adjusted models, prestroke statins use was associated with reduced 3-month mortality [adjusted OR, 0.38; 95% CI, 0.16–0.91; P=0.031)], major disability (adjusted OR, 0.38; 95%CI, 0.15–0.99; P=0.047), and composite outcome (adjusted OR, 0.31; 95% CI,0.17–0.74; P=0.009). Conclusions: Prestroke statins use can reduce plasma Ox-LDL levels and improve clinical outcomes in patients with AF-related AIS.

scholarly journals Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke

2019 ◽  
Author(s):  
lanying he ◽  
Ronghua Xu ◽  
Jian Wang ◽  
LIli Zhang ◽  
Lijuan Zhang ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Clinical Outcomes ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Low Density ◽  
Composite Outcome ◽  
Oxidized Low Density Lipoprotein

Abstract Background: Atrial fibrillation (AF) is a common cause of cerebral infarction, which could lead to endothelial dysfunction, increased reactive oxygen species (ROS) and oxidized low density lipoprotein (Ox-LDL).AF is associated with higher mortality and more severe neurologic disability. Statins may exert neuroprotective effects that are independent of LDL-C lowering. The purpose of our study was to investigate whether prestroke statins use could reduce plasma Ox-LDL levels and improve clinical outcomes in patients with AF-related acute ischemic stroke (AIS). Methods: This was a multicenter prospective study that involved four medical centers, 242 AIS patients with AF were identified, who underwent a comprehensive clinical investigation and a 72h-Holter electrocardiogram monitoring. All patients were divided into two groups: prestroke statins use and n o prestroke statins use groups , who were followed up for 3 months. Plasma Ox-LDL levels were measured using enzyme-linked immunosorbent assay (ELISA) on admission and at 3 months. The outcome was death, major disability (modified Rankin Scale score≥3), and composite outcome (death/major disability) at 3 months after AIS. Results: 136 patients were in no prestroke statins use group, and 106 in prestroke statins use group . Plasma Ox-LDL levels were significantly lower in prestroke statins use than in no prestroke statins use on admission and at 3 months (P<0.001). Plasma Ox-LDL levels on admission were associated with 3-month mortality [adjusted odds ratio (OR), 1.05; 95% confidence interval(CI), 0.99-1.12; P=0.047]. In fully adjusted models, prestroke statins use was associated with reduced 3-month mortality [adjusted OR, 0.38; 95% CI, 0.16–0.91; P=0.031)], major disability (adjusted OR, 0.38; 95%CI, 0.15–0.99; P=0.047), and composite outcome (adjusted OR, 0.31; 95% CI,0.17–0.74; P=0.009). Conclusions: Prestroke statins use can reduce plasma Ox-LDL levels and improve clinical outcomes in patients with AF-related AIS.

scholarly journals Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Level is Related to Clinical Prognosis In Patients with Acute Atherosclerosis-related Ischemic Stroke

2021 ◽  
Vol 27 ◽  
pp. 107602962110595
Author(s):  
Xiaoli Yang ◽  
Duanlu Hou ◽  
Jianjun Liu ◽  
Tianyao Wang ◽  
Yufan Luo ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Functional Outcome ◽  
Clinical Response ◽  
Infarct Volume ◽  
Low Density Lipoprotein ◽  
Rank Correlation ◽  
Density Lipoprotein ◽  
Clinical Prognosis ◽  
Density Lipoprotein Receptor ◽  
Favorable Functional Outcome

To investigate the associations between soluble Lectin-like Oxidized Low-density lipoprotein receptor-1 (sLOX-1) and clinical prognosis, especially infarct volume in patients with acute atherosclerosis-related ischemic stroke. We recruited acute ischemic stroke patients within 3 days after onset. Patients were stratified into 3 groups by sLOX-1 level. Initial stroke severity was assessed using the National Institutes of Health Stroke Scale scores, and infarct volume was measured using DWI by ITK-SNAP software. The clinical prognosis was evaluated by DWI volume, clinical response at discharge, and functional outcome at 90 days. Spearman rank correlation analysis was used to examine associations between circulating sLOX-1 levels and infarct volumes. Logistic regression was used to explore the relationship between sLOX-1 levels and clinical prognosis. A total of 207 patients were included in our study. The median DWI volume in the lowest sLOX-1 tertile was 1.98 cm3, smaller than 4.26 cm3 in the highest sLOX-1 group. The Spearman rank correlation coefficient between sLOX-1 levels and DWI volume was 0.47 ( P < .01). Compared with the highest sLOX-1 tertiles, patients in the lowest sLOX-1 tertile had a higher risk of favorable functional outcome at 90 days (OR = 3.47, 95% CI, 1.21-9.96) after adjusting traditional risk factors. However, there was no difference between sLOX-1 level and clinical response at discharge. For patients with acute atherosclerosis-related ischemic stroke, circulating sLOX-1 level is correlated with DWI volume in the acute phase and favorable functional outcome at 90 days, but not with the clinical response at discharge.

scholarly journals Resolution of Inflammation is Disturbed in Macrophages of Diabetic Patients with Acute Ischemic Stroke

2021 ◽  
Author(s):  
Xin Tang ◽  
Zhijuan Miao ◽  
Lan Liu ◽  
Jiawei Zhang ◽  
Xiaolong Cai ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Diabetic Patients ◽  
Low Density ◽  
Oxidized Low Density Lipoprotein ◽  
Resolution Function ◽  
Resolution Of Inflammation ◽  
Inflammatory Signals

Abstract Background: Inflammation plays an important role in diabetes mellitus (DM) and its related complications, including atherosclerosis and acute ischemic stroke (AIS). The mechanisms of excessive inflammation in DM are not fully understood. Specialized pro-resolving mediators (SPMs) are key regulators that promote resolution of inflammation. Unbalance of pro-resolving and pro-inflammatory signals may be the key pathogenesis in DM and DM-related diseases. We examined the resolution function in macrophages of DM patients with AIS.Methods: Macrophages were derived from peripheral blood mononuclear cells of AIS and none-AIS patients with or without DM. The cultured macrophages were treated with oxidized low-density lipoprotein. Resolution and inflammatory pathway markers were analyzed in the culture medium and cells. Results: In AIS patients, the ratios of SPMs to leukotriene B4 (LTB4) released by macrophages were decreased in those with DM compared to those without DM. Oxidized low-density lipoprotein treatment further reduced the ratios of SPMs/LTB4 in DM patients with AIS, but such a reduction was not observed in none-DM AIS patients. Analysis of M2/M1 polarization and MAPK/NFkB pathway markers also demonstrated un-resolved inflammation in macrophages of AIS patients with DM. Treatment with one of the SPMs, resolvin D2, rescued the resolution function and ameliorated inflammation in macrophages from these patients.Conclusions: Our data demonstrated that resolution of inflammation is disturbed by DM in macrophages of AIS patients, implicating a novel mechanism of un-resolved inflammation in DM-related vascular disorder. Exogenous SPMs treatment can rescue resolution and downregulate inflammatory signals, and may thus be beneficial in DM-related AIS.

Sign in / Sign up

Export Citation Format

Share Document